Table 13.
Resection extent for LG and HG tumors: summary of studies reporting influence of resection extent on outcome for LG tumors (upper part) and HG tumors (lower part)
| Author (reference) | Quality | Year | Patients | EOR | Patients | Outcome studied | Result | Comment |
|---|---|---|---|---|---|---|---|---|
| Guidetti [20] | B | 1981 | 53 | GTR | 2 | Mean survival (months) | 25 | p NR |
| PR | 17 | 98 | ||||||
| Bio + myelotomy | 29 | 72 | ||||||
| Bio + decompression | 5 | 45 | ||||||
| Rossitch [61] (p) | B | 1990 | 12 | GTR | 4 | Recurrence (%) | 25 | p NR |
| STR/Bio | 8 | 37.5 | ||||||
| Epstein [15] | A | 1992 | 17 | GTR | 17 | Recurrence (%) | 0 | Mean FU 50.2 months |
| Cristante [11] | B | 1994 | 17 | GTR | 8 | Recurrence (%) | 0 | p NR |
| quasi-GTR | 3 | 0 | ||||||
| PR | 6 | 33 | ||||||
| Innocenzi [26] (p) | B | 1996 | 29 | GTR | 10 | Mean survival (months) | 114 | p NR, NS |
| STR | 11 | 109 | ||||||
| Bio | 8 | 84 | ||||||
| Innocenzi [27] | B | 1997 | 29 | GTR | 10 | Median survival (months) | 114 | gr. I patients p NR |
| STR | NR | 110 | ||||||
| Bio | NR | 84 | ||||||
| 26 | STR | NR | Median survival (months) | 72 | gr. II patients | |||
| Bio | NR | 62 | p NR | |||||
| Bouffet [5] (p) | A | 1998 | 49 | GTR/STR | 21 | 10-year OS (%) | 67 | p = 0.57 |
| PR/Bio | 28 | 76 | ||||||
| Constantini [9] (p) | A | 2000 | 58 | GTR | NR | 10-year PFS | NR | NS GTR v. STR |
| STR | GTR/STR v. PR: p = 0.0017 | |||||||
| PR | PR < 80% | |||||||
| Kim [34] | A | 2001 | 18 | GTR/STR | NR | Median survival (months) | NR | p = 0.65 |
| PR/Bio | NR | NR | ||||||
| Jallo [28] | A | 2001 | 17 | GTR | 12 | 5-year/10-year OS (%) | 82/82 | “GTR + STR equally efficacious for long-term survival” |
| STR | 5 | All patients | ||||||
| Robinson [59] | A | 2005 | 14 | GTR/STR | 7 | 10-year PFS/OS (%) | 100/100 | PFS p = 0.0746 |
| Bio | 7 | 60/60 | OS p = 0.0979 | |||||
| Nakamura [51] | B | 2006 | 18 | GTR/PR | 9 | Estimate 10-year OS (%) | 80 (↑) | p = 0.0251 |
| Bio | 9 | 32 (↓) | ||||||
| Nakamura [52] | B | 2008 | 11 | GTR/STR | 6 | Survival (%) | 100 | Not significant |
| PR/Bio | 5 | NR | Small sample size | |||||
| Epstein [15] | A | 1992 | 6 | GTR | 6 | Recurrence (%) | 100 | Mean survival 8.6 moths |
| Cristante [11] | B | 1994 | 17 | quasi-GTR | 3 | Recurrence (%) | 100 | p NR |
| PR | 3 | 100 | ||||||
| Innocenzi [27] | B | 1997 | 10 | STR | NR | Median survival (months) | 18 | gr. III patients |
| Bio | NR | 14 | p NR | |||||
| Bouffet [5] (p) | A | 1998 | 24 | GTR/STR | 10 | 10-year OS (%) | 38 | p = 0.63 |
| PR/Bio | 14 | 26 | ||||||
| Kim [34] | A | 2001 | 10 | GTR/STR | NR | Median survival (months) | NR | p = 0.91 |
| PR/Bio | NR | NR | ||||||
| Santi [65] (m) | B | 2003 | 36 | GTR | 7 | Median survival (months) | 14 | p = 0.118 |
| STR | 11 | 18 | ||||||
| Bio | 16 | 12 | ||||||
| Nakamura [51] | B | 2006 | 12 | GTR/PR | 5 | Estimate 5-year OS (%) | 68 (↑) | p = 0.0342 |
| Bio | 7 | 0 (↓) | ||||||
| McGirt [46] (m) | A | 2008 | 27 | GTR | 12 | 4-year OS (%) | 78 (↑) | Univariate p = 0.028 |
| STR | 15 | 38 (↓) | Multivariate p NS | |||||
| gr. III patients | ||||||||
| Nakamura [52] | B | 2008 | 12 | GTR/STR | 4 | Death (%) | 50 | Not significant |
| PR/Bio | 8 | 86 | Small sample size |
↑ positive influence on outcome measure, ↓ negative influence on outcome measure